Article Sidebar

Published: 2021-12-09
Abstract Views: 194
DOI: https://doi.org/10.52163/yhc.v62i7%20(2021).212
Issue
Vol. 62 No. 7 (2021)
Section
Articles
How to Cite
Hạnh, N. T. ., & Dũng, T. Q. (2021). EFFECTIVENESS OF RESPIRATORY REHABILITATION FOR POMPE PATIENTS. Vietnam Journal of Community Medicine, 62(7 (2021). https://doi.org/10.52163/yhc.v62i7 (2021).212

EFFECTIVENESS OF RESPIRATORY REHABILITATION FOR POMPE PATIENTS

Nguyen Thi Hanh1, Trinh Quang Dung2
1 Hanoi Medical University
2 National Hospital of Pediatrics

Main Article Content

Abstract

Objectives: To assess the effectiveness of respiratory rehabilitation for Pompe patients at National Hospital of Pediatrics. Subjects and methods: The non-controlled clinical intervention study of 21 Pompe patients who were treated for rehabilitation at National Hospital of Pediatrics. All patients were objectively evaluated before and after 4 weeks of intervention. Result: In this study, there were statistically significant improvements of respiratory and motor development over 4 weeks of treatment (p < 0,05), with heartbeats from 98,57 ± 10,92 down to 94,29 ± 10,16 points; breathiness from 33,21 ± 8,68 down to 30,43 ± 7,46 points; SpO2 from 96,14 ± 1,10 up to 96,79 ± 0,98 points; % GMFM from 55,43 ± 33,23 up to 58,05 ± 32,87 percent. Conclusions: There were improvements of respiratory and motor development for Pompe patients after intervention.

Article Details

Keywords

Rehabilitation, respiratory, Pompe.

References

1. National Organization for Rare Disorders, Pompe Disease, https://rarediseases.org/rare-diseases/pompe-disease/, 2017, Accessed June 2020.
2. Hai LT, Hear Our Stories. Hanoi Labour publishing house, 2018.
3. Pompe Community. Pompe Disease Statistics, https://www.pompe.com/en/patients/inheriting-pompe/statistics.aspx, 2017. Accessed June 2020
4. Van Capelle CI., Childhood Pompe disease: clinical spectrum and genotype in 31 patients, Orphanet J Rare Dis,2016 ; 11- 65.
5. Kishnani PS, Corzo D, Leslie ND et al., Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease., Pediatric Res, 2019; 66: 329–335.
6. Hagemans ML, Winkel LP, Van Doorn PA et al., Clinical manifestation and natural course of late-onset Pompe’s disease in 54 Dutch patients., Brain, 2005; 128: 671–677.
7. Berger KI, Chan Y, Rom WN et al., Progression from respiratory dysfunction to failure in late-onset Pompe disease, Neuromuscul. Disord, 2016; 26: 481–489.
8. Falk DJ, Todd AG, Lee S et al., Peripheral nerve and neuromuscular junction pathology in Pompe disease, Hum Mol Genet, 2015; 24: 625–636.
9. Regnery C, Kornblum C, Hanisch F et al., 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy, J. Inherit. Metab, 2012; 35: 837–845.
10. Fatma AJ, Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: Consensus recommendations from an expert group, BMC Neurology, 2015; 15(1).
11. Terzis G, Effect of aerobic on late-onset Pompe disease receiving enzyme replacement therapy, Mcl Genet Metab, 2011; 104: 233-279.
12. Strothotte S, Enzyme replacement therapy with alglucosidase alfa with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial, J Neurol, 2010; 257: 91-97.